Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept crossover study of BGG492 for tinnitus
2010-022166-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selurampanel in tinnitus (2 arms), sponsored by Novartis. Primary endpoint: Tinnitus loudness (current) after multiple dose treatment. Started Oct 2010; status: completed.
02
Drugs
selurampanel
03
Conditions
tinnitus
Beyond the preview
Go deeper on 2010-022166-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022166-27.